Aziz M Mezlini1,2, Colin Magdamo1, Emily Merrill1, Lori B Chibnik1,2,3, Deborah L Blacker3,4, Bradley T Hyman1,2, Sudeshna Das1,2. 1. MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA, USA. 2. Department of Neurology, Harvard Medical School, Boston, MA, USA. 3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 4. Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: The APOEɛ4 allele is the largest genetic risk factor for late-onset Alzheimer's disease (AD). Recent literature suggested that the contribution of APOEɛ4 to AD risk could be population-specific, with ɛ4 conferring a lower risk to Blacks or African Americans. OBJECTIVE: To investigate the effect of APOE haplotypes on AD risk in individuals with European ancestry (EU) and Blacks or African Americans (AA). METHODS: We selected data from 1) the National Alzheimer's Coordinating Center: a total of 3,486 AD cases and 4,511 controls (N = 7,997, 60% female) with genotypes from the Alzheimer's Disease Genetics Consortium (ADGC), and 2) the Rush University Religious Orders Study and Memory and Aging Project (ROSMAP) cohort with 578 AD and 670 controls (N = 1,248, 60% female). Using ɛ3 homozygotes as the reference, we compared the association of various APOE haplotypes with the clinical and neuropathological correlates of dementia in AA and EU. RESULTS: In both cohorts, we find no difference in the odds or age of onset of AD among the ɛ4-linked haplotypes defined by rs769449 within either AA or EU. Additionally, while APOEɛ4 was associated with a faster rate of decline, no differences were found in rate of decline, clinical or neuropathological features among the ɛ4-linked haplotypes. Further analysis with other variants near the APOE locus failed to identify any effect modification. CONCLUSION: Our study finds similar effects of the ɛ4-linked haplotypes defined by rs769449 on AD as compared to ɛ3 in both AA and EU. Future studies are required to understand the heterogeneity of APOE conferred risk of AD among various genotypes and populations.
BACKGROUND: The APOEɛ4 allele is the largest genetic risk factor for late-onset Alzheimer's disease (AD). Recent literature suggested that the contribution of APOEɛ4 to AD risk could be population-specific, with ɛ4 conferring a lower risk to Blacks or African Americans. OBJECTIVE: To investigate the effect of APOE haplotypes on AD risk in individuals with European ancestry (EU) and Blacks or African Americans (AA). METHODS: We selected data from 1) the National Alzheimer's Coordinating Center: a total of 3,486 AD cases and 4,511 controls (N = 7,997, 60% female) with genotypes from the Alzheimer's Disease Genetics Consortium (ADGC), and 2) the Rush University Religious Orders Study and Memory and Aging Project (ROSMAP) cohort with 578 AD and 670 controls (N = 1,248, 60% female). Using ɛ3 homozygotes as the reference, we compared the association of various APOE haplotypes with the clinical and neuropathological correlates of dementia in AA and EU. RESULTS: In both cohorts, we find no difference in the odds or age of onset of AD among the ɛ4-linked haplotypes defined by rs769449 within either AA or EU. Additionally, while APOEɛ4 was associated with a faster rate of decline, no differences were found in rate of decline, clinical or neuropathological features among the ɛ4-linked haplotypes. Further analysis with other variants near the APOE locus failed to identify any effect modification. CONCLUSION: Our study finds similar effects of the ɛ4-linked haplotypes defined by rs769449 on AD as compared to ɛ3 in both AA and EU. Future studies are required to understand the heterogeneity of APOE conferred risk of AD among various genotypes and populations.
Authors: Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine Journal: Alzheimers Dement Date: 2012-01 Impact factor: 21.566
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: Hugh C Hendrie; Jill Murrell; Olusegun Baiyewu; Kathleen A Lane; Christianna Purnell; Adesola Ogunniyi; Frederick W Unverzagt; Kathleen Hall; Christopher M Callahan; Andrew J Saykin; Oye Gureje; Ann Hake; Tatiana Foroud; Sujuan Gao Journal: Int Psychogeriatr Date: 2014-02-24 Impact factor: 3.878
Authors: Elizabeth E Blue; Andréa R V R Horimoto; Shubhabrata Mukherjee; Ellen M Wijsman; Timothy A Thornton Journal: Alzheimers Dement Date: 2019-10-09 Impact factor: 21.566
Authors: Xiaopu Zhou; Yu Chen; Kin Y Mok; Timothy C Y Kwok; Vincent C T Mok; Qihao Guo; Fanny C Ip; Yuewen Chen; Nandita Mullapudi; Paola Giusti-Rodríguez; Patrick F Sullivan; John Hardy; Amy K Y Fu; Yun Li; Nancy Y Ip Journal: Nat Commun Date: 2019-07-25 Impact factor: 14.919
Authors: S Hong Lee; Denise Harold; Dale R Nyholt; Michael E Goddard; Krina T Zondervan; Julie Williams; Grant W Montgomery; Naomi R Wray; Peter M Visscher Journal: Hum Mol Genet Date: 2012-11-28 Impact factor: 6.150
Authors: Sandra Weintraub; Lilah Besser; Hiroko H Dodge; Merilee Teylan; Steven Ferris; Felicia C Goldstein; Bruno Giordani; Joel Kramer; David Loewenstein; Dan Marson; Dan Mungas; David Salmon; Kathleen Welsh-Bohmer; Xiao-Hua Zhou; Steven D Shirk; Alireza Atri; Walter A Kukull; Creighton Phelps; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2018 Jan-Mar Impact factor: 2.703